Chase Investment Counsel’s PRA Health Sciences, Inc. PRAH Stock Holding History

Chase Investment Counsel’s Portfolio PRAH Stock Details PRAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,457	Closed	-$1.81M	–	110
2019 Q1	$1.81M	Buy	16,457 +630	+4%	+$65.8K	0.93%	36
2018 Q4	$1.46M	Sell	15,827 -1,158	-7%	-$117K	0.87%	37
2018 Q3	$1.87M	Buy	16,985 +282	+2%	+$29.4K	0.96%	38
2018 Q2	$1.56M	Sell	16,703 -6,576	-28%	-$566K	0.84%	37
2018 Q1	$1.93M	Buy	23,279 +255	+1%	+$22.7K	1%	37
2017 Q4	$2.1M	Sell	23,024 -930	-4%	-$77.4K	1.1%	36
2017 Q3	$1.82M	Sell	23,954 -4,870	-17%	-$368K	0.96%	37
2017 Q2	$2.16M	Buy	28,824 +2,976	+12%	+$206K	1.05%	36
2017 Q1	$1.69M	Buy	25,848 +11,713	+83%	+$690K	0.81%	39
2016 Q4	$779K	Buy	14,135 +4,255	+43%	+$234K	0.39%	61
2016 Q3	$558K	Buy	+9,880	New	+$484K	0.25%	73

Other funds holding PRAH

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Chase Investment Counsel's PRAH Position: Q2 2019 in Review

Chase Investment Counsel sold out of PRA Health Sciences, Inc. (PRAH) in Q2 2019, closing a stake of 16,457 shares — an estimated $1.81M sold.

Chase Investment Counsel first reported a position in PRAH in Q3 2016 and held it in 11 quarters. The position peaked at $2.16M in Q2 2017. 329 funds tracked by Wall St. Rank hold PRAH as of Q2 2019.

Chase Investment Counsel reported no remaining PRA Health Sciences, Inc. position as of Q2 2019 after selling out during the quarter.
Chase Investment Counsel sold 16,457 PRA Health Sciences, Inc. shares in Q2 2019, an estimated $1.81M.
Chase Investment Counsel first reported a position in PRA Health Sciences, Inc. in Q3 2016 and held it in 11 quarters.
Chase Investment Counsel's PRA Health Sciences, Inc. position peaked at $2.16M in Q2 2017.
329 funds tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q2 2019.

Based on Chase Investment Counsel's 13F filing for Q2 2019, filed 7 Aug 2019.